Now, Gilead has conducted an analysis of a phenomenon that can undermine all infectious disease therapies, including lenacapavir—HIV’s ability to evolve resistance to the breakthrough antiviral.

Since its first approval in 2022, Gilead Sciences’ lenacapavir—a twice-yearly injectable—has come to be a potential game ...

Lenacapavir (LEN) is an antiviral medication used to treat and prevent HIV/AIDS and was first approved for individuals with ...

Scientists found that nasal cells act as a first line of defense against the common cold, working together to block ...

When a rhinovirus, the most frequent cause of the common cold, infects the lining of our nasal passages, our cells work ...

A new study shows that the body’s early immune response, not the virus itself, often determines how severe a rhinovirus cold ...

Baculoviruses are a diverse group of insect viruses that have long served as both biological control agents in agriculture and versatile tools in biotechnology. Their life cycle is marked by two ...

Members of a new class of antivirals are being tested in U.S. clinical trials, and one has gained approval in Japan, but how ...

Across the world, only a few dozen people appear to carry a genetic glitch that lets them brush off viruses that flatten ...